The Klebsiella pneumoniae Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Klebsiella pneumoniae Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued products.
GlobalData tracks 64 drugs in development for Klebsiella pneumoniae Infections by 57 companies/universities/institutes. The top development phase for Klebsiella pneumoniae Infections is preclinical with 44 drugs in that stage. The Klebsiella pneumoniae Infections pipeline has 53 drugs in development by companies and 11 by universities/ institutes. Some of the companies in the Klebsiella pneumoniae Infections pipeline products market are: ContraFect, Akthelia Pharmaceuticals and Pedanius Therapeutics.
The key targets in the Klebsiella pneumoniae Infections pipeline products market include UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC 3.5.1.108), Penicillin Binding Protein (PBP), and Bacterial Cell Wall.
The key mechanisms of action in the Klebsiella pneumoniae Infections pipeline product include UDP-3-O-[3-Hydroxymyristoyl] N-Acetylglucosamine Deacetylase (UDP-3-O-Acyl-N-Acetylglucosamine Deacetylase or Protein EnvA or lpxC or EC 3.5.1.108) Inhibitor with three drugs in Preclinical. The Klebsiella pneumoniae Infections pipeline products include six routes of administration with the top ROA being Oral and 15 key molecule types in the Klebsiella pneumoniae Infections pipeline products market including Small Molecule, and Biologic.
Klebsiella pneumoniae Infections overview
Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs, and is very common in patients with underlying diseases like diabetes, chronic lung disease, and alcoholism. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune systems. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, headache, and chest pain. Treatment includes antibiotics and hygienic lifestyle.
For a complete picture of Klebsiella pneumoniae Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
